Anxiety and depression symptoms after COVID-19 infection: results from the COVID Symptom Study app.
Journal
medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986
Informations de publication
Date de publication:
08 Jul 2021
08 Jul 2021
Historique:
entrez:
16
7
2021
pubmed:
17
7
2021
medline:
17
7
2021
Statut:
epublish
Résumé
Mental health issues have been reported after SARS-CoV-2 infection. However, comparison to prevalence in uninfected individuals and contribution from common risk factors (e.g., obesity, comorbidities) have not been examined. We identified how COVID-19 relates to mental health in the large community-based COVID Symptom Study. We assessed anxiety and depression symptoms using two validated questionnaires in 413,148 individuals between February and April 2021; 26,998 had tested positive for SARS-CoV-2. We adjusted for physical and mental pre-pandemic comorbidities, BMI, age, and sex. Overall, 26.4% of participants met screening criteria for general anxiety and depression. Anxiety and depression were slightly more prevalent in previously SARS-CoV-2 positive (30.4%) vs. negative (26.1%) individuals. This association was small compared to the effect of an unhealthy BMI and the presence of other comorbidities, and not evident in younger participants (≤40 years). Findings were robust to multiple sensitivity analyses. Association between SARS-CoV-2 infection and anxiety and depression was stronger in individuals with recent (<30 days) vs. more distant (>120 days) infection, suggesting a short-term effect. A small association was identified between SARS-CoV-2 infection and anxiety and depression symptoms. The proportion meeting criteria for self-reported anxiety and depression disorders is only slightly higher than pre-pandemic. Zoe Limited, National Institute for Health Research, Chronic Disease Research Foundation, National Institutes of Health, Medical Research Council UK.
Sections du résumé
BACKGROUND
BACKGROUND
Mental health issues have been reported after SARS-CoV-2 infection. However, comparison to prevalence in uninfected individuals and contribution from common risk factors (e.g., obesity, comorbidities) have not been examined. We identified how COVID-19 relates to mental health in the large community-based COVID Symptom Study.
METHODS
METHODS
We assessed anxiety and depression symptoms using two validated questionnaires in 413,148 individuals between February and April 2021; 26,998 had tested positive for SARS-CoV-2. We adjusted for physical and mental pre-pandemic comorbidities, BMI, age, and sex.
FINDINGS
RESULTS
Overall, 26.4% of participants met screening criteria for general anxiety and depression. Anxiety and depression were slightly more prevalent in previously SARS-CoV-2 positive (30.4%) vs. negative (26.1%) individuals. This association was small compared to the effect of an unhealthy BMI and the presence of other comorbidities, and not evident in younger participants (≤40 years). Findings were robust to multiple sensitivity analyses. Association between SARS-CoV-2 infection and anxiety and depression was stronger in individuals with recent (<30 days) vs. more distant (>120 days) infection, suggesting a short-term effect.
INTERPRETATION
CONCLUSIONS
A small association was identified between SARS-CoV-2 infection and anxiety and depression symptoms. The proportion meeting criteria for self-reported anxiety and depression disorders is only slightly higher than pre-pandemic.
FUNDING
BACKGROUND
Zoe Limited, National Institute for Health Research, Chronic Disease Research Foundation, National Institutes of Health, Medical Research Council UK.
Identifiants
pubmed: 34268526
doi: 10.1101/2021.07.07.21260137
pmc: PMC8282115
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : EPA
ID : EP-W-17-011
Pays : United States
Organisme : NIDDK NIH HHS
ID : K23 DK125838
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NIDDK NIH HHS
ID : K01 DK120742
Pays : United States
Organisme : Medical Research Council
ID : MC_PC_20058
Pays : United Kingdom
Commentaires et corrections
Type : UpdateIn
Références
Brain Behav Immun. 2020 Oct;89:531-542
pubmed: 32485289
Lancet Psychiatry. 2021 May;8(5):416-427
pubmed: 33836148
Brain. 2020 Oct 1;143(10):3104-3120
pubmed: 32637987
Cell. 2020 Oct 1;183(1):16-27.e1
pubmed: 32882182
Nat Rev Immunol. 2020 Nov;20(11):645-646
pubmed: 33024283
Neurology. 2020 Sep 29;95(13):e1868-e1882
pubmed: 32680942
Nat Rev Neurol. 2020 Nov;16(11):636-644
pubmed: 32839585
Sci Data. 2021 Nov 22;8(1):297
pubmed: 34811392
EClinicalMedicine. 2021 Jan 07;31:100683
pubmed: 33490928
Lancet Psychiatry. 2020 Jul;7(7):611-627
pubmed: 32437679
Br J Psychiatry. 2021 Jun;218(6):326-333
pubmed: 33081860
Nat Med. 2020 Jul;26(7):1037-1040
pubmed: 32393804
Ann Intern Med. 2007 Mar 6;146(5):317-25
pubmed: 17339617
Lancet Psychiatry. 2021 Feb;8(2):130-140
pubmed: 33181098
BJPsych Open. 2021 May 18;7(3):e104
pubmed: 34001295
Lancet Psychiatry. 2020 Jun;7(6):547-560
pubmed: 32304649
Lancet Psychiatry. 2020 Oct;7(10):875-882
pubmed: 32593341
Nat Neurosci. 2021 Feb;24(2):168-175
pubmed: 33257876
Lancet Neurol. 2020 Sep;19(9):767-783
pubmed: 32622375
Nat Neurosci. 2021 Mar;24(3):368-378
pubmed: 33328624
Med Care. 2003 Nov;41(11):1284-92
pubmed: 14583691
Lancet Psychiatry. 2020 Oct;7(10):883-892
pubmed: 32707037